[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-459077-105":3,"detail-sidebar-cat-0-en-105":84,"doc-detail-459077-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":77,"head_meta":79,"extra_data":81,"updated_unix":83},105,"en","early-detection-and-management-of-alzheimers-disease-through-multi-omic-analysis-of-blood","Early detection and management of Alzheimer’s Disease through multi-omic analysis of blood","","Alzheimer’s disease (AD) is a major driver of dementia, and symptom-based identification often misses the opportunity for early intervention. A Molecular You (MY) two-sided platform addresses this gap by quantifying 280 plasma metabolites and proteins and using algorithms to rank health risks with an average predictive value of 88% across 20+ systems and pathways. The study analyzes plasma from 74 fasting patients using LC-MS/MS metabolomics and proteomics, then maps risks and biological pathways to AD endotypes.",{"@graph":14,"@context":76},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-detection-and-management-of-alzheimers-disease-through-multi-omic-analysis-of-blood/459077/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-detection-and-management-of-alzheimers-disease-through-multi-omic-analysis-of-blood/459077.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68,72],{"name":59,"@type":60,"acceptedAnswer":61},"What problem does the study target in Alzheimer’s disease care?","Question",{"text":62,"@type":63},"The study targets the limitations of symptom-based AD identification, which can delay early intervention and worsen clinical outcomes.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How does the Molecular You (MY) platform support AD risk assessment?",{"text":67,"@type":63},"MY quantifies 280 plasma metabolites and proteins with absolute quantification and ranks health risks while providing pathway and systems insights using predictive algorithms.",{"name":69,"@type":60,"acceptedAnswer":70},"What did the study find when comparing diagnosed AD patients and overall risk groups?",{"text":71,"@type":63},"Four of five diagnosed AD patients were confirmed, one aligned more with vascular dementia, and 36 additional patients were classified as moderate to high AD risk.",{"name":73,"@type":60,"acceptedAnswer":74},"How are patient care plans intended to be improved based on the analysis?",{"text":75,"@type":63},"Findings are used to stratify patients into AD endotypes and develop personalized preventive plans, incorporating targeted dietary, lifestyle, and clinical interventions.","https://schema.org",{"og:url":32,"og:type":78,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":80,"canonical":32},"index,follow",{"doc_id":82,"site_id":7},459077,1790755140,{"code":4,"msg":85,"data":86},"success",[87,91,95,99,104,109,113,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},"Exam",70,"exam",{"id":100,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},5,"Comic",60,"comic",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},6,"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":111,"slug":112},7,40,"healthcare",{"id":114,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},8,"Research & Report",30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":100,"slug":133},19,"General","general",{"code":4,"msg":85,"data":135},{"doc_id":82,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":110,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":83,"read_time":100,"preview_page_count":4},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10. 1002/alz70856_105281  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nEarly detection and management of Alzheimer’s Disease through multi-omic analysis of blood  \nMohammad Anwar  Brandon Landry  Windy Wang  Karm Alhasan  Haiyan Yang  Robert Fraser  \nMolecular You, Vancouver, BC, Canada  \nCorrespondence  \nMohammad Anwar, Molecular You, Vancouver, BC, Canada.  \nEmail: [ash.anwar@molecularyou.com](ash.anwar@molecularyou.com)  \nAbstract  \nBackground: Alzheimer’s disease (AD), a leading cause of dementia, poses a global health challenge as aging populations expand. Traditionally, practitioners rely on symptom-based identification, often miss the critical window for early intervention, limiting opportunities for improved clinical outcomes. Molecular You (MY) has developed an innovative, two-sided platform to address this gap. The platform i) quantifies 280 high-value plasma metabolites and proteins with absolute quantification and ii) through its algorithms ranks health risks and provides insights across more than 20 biological systems and pathways with an average predictive value of 88%.  \nThis study demonstrates the value of applying the MY platform in identifying AD risk and associated co-morbidities early, stratifying patients into endotype-specific mechanisms that inform customized care plans.  \nMethod: Plasma samples from 74 patients, including 5 diagnosed with AD, were collected after an overnight fast, rapidly frozen, and shipped to MY for analysis. Each specimen underwent quantitative metabolomic (143 metabolites) and proteomic (140 proteins) assays using well-established LC-MS/MS methods. The resulting data were processed through the MY platform to identify health risks and map key biological pathways.  \nResult: Four of the five patients diagnosedwithAD were confirmed,while one patient’s profile was more aligned with vascular dementia. Additionally, 36 patients were identified at moderate to high risk for AD. Analysis of the biological pathways revealed several distinct endotypes for AD risk: dyslipidemia/ abnormal lipid metabolism, metabolic aberrations, inflammation and oxidative stress driving neuroinflammation and neurodegeneration, and neurotransmitter dysfunction leading to excitotoxicity and synaptic dysfunction. Several co-morbidities were identified in the population, including metabolic health issues such as diabetes, kidney health, liver health, immune  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e105281.  \n[https://doi.org/10.1002/alz70856_105281](https://doi.org/10.1002/alz70856_105281)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of2  \nBIOMARKERS  \nhealth, cardiovascular disease, and inflammatory bowel disease. Personalized care plans were developed based on these findings, incorporating targeted dietary, lifestyle, and clinical interventions.  \nConclusion: The MY platform demonstrates the feasibility of multi-omic analysis of blood to enhance the early detection of AD before clinical symptoms manifest, identify emerging co-morbidities, stratify patients into AD endotypes enabling precision preventative and personalized care. By monitoring patients longitudinally using the MY platform it will be possible to objectively quantify treatment efficacy, safety and overall patient outcomes.","cbCain5WKTzV3cyE","https://ap.wps.com/l/cbCain5WKTzV3cyE","pdf",328564,"English","# Abstract\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"What problem does the study target in Alzheimer’s disease care?\",\"answer\":\"The study targets the limitations of symptom-based AD identification, which can delay early intervention and worsen clinical outcomes.\"},{\"question\":\"How does the Molecular You (MY) platform support AD risk assessment?\",\"answer\":\"MY quantifies 280 plasma metabolites and proteins with absolute quantification and ranks health risks while providing pathway and systems insights using predictive algorithms.\"},{\"question\":\"What did the study find when comparing diagnosed AD patients and overall risk groups?\",\"answer\":\"Four of five diagnosed AD patients were confirmed, one aligned more with vascular dementia, and 36 additional patients were classified as moderate to high AD risk.\"},{\"question\":\"How are patient care plans intended to be improved based on the analysis?\",\"answer\":\"Findings are used to stratify patients into AD endotypes and develop personalized preventive plans, incorporating targeted dietary, lifestyle, and clinical interventions.\"}]","Early detection and management of Alzheimer’s Disease through multi-omic analysis of blood | PDF"]